Office of Health Economics

Not following anyone yet

adrian towse antibiotics biotechnology and pharmaceuticals cancer england eq-5d europe health care health economics health technology assessment hta htai innovation ispor medicine medicines nhs nice ohe pharmaceutical industry pharmaceuticals pricing proms r&d reimbursement uk more…

2018 aai access access to care adolescents adrian towse affordability amr antibacterials antibiotics antimicrobial resistance antimicrobials antipsychotics approaches to value assessment asia assessment augmented cea australia barcelona big data biosimilars biotechnology and pharmaceuticals brazil buget burden of illness cadth cancer caregiving cea challenges children china clinical evaluation clinical trial commissioning competition consent contracting cost cost effectiveness cost of r&d cost-effectiveness cost-effectiveness analysis cost-effectiveness threshold costa rica costs curative therapies daas data analytics debate decision analysis decision modelling devlin diabetic retinopathy diagnostics differential pricing direct acting antivirals discrete choice discrete choice experiment disease management drug development drugs economics economics of cures economics of r&d ed-5d elderly ema emerging markets end of life end of life medicines end-of-life end-of-life care england eq-5d eq-5d-3l eq-5d-5l eq-5d-y eq-vas europe euroqol evidence uncertainty expenditure expenditure caps fair pricing fairness financial incentives flexibility and transparency forecast framing effects france funding future directions gdpr generic competition generics genomic testing genomics germany global engagement global health globalisation good practice handling uncertainty healtcare decision making health care health care costs health care systems health data health economics health financing health inequality health insurance health outcomes health policy health status health system capacity health technology assessment healthcare heath technology assessment (hta) heor hepatitis c hip surgery hta hta decision making hta lifecycle hta outcomes hta transferability htai icer impact incentives indication indication based pricing indication specific pricing indication-based pricing indication-based-pricing indication-specific pricing inequality innovation innovative medicine innovative payment models intellectual property international comparisons international volunteering interviews ipor washing dc ispe ispor ispor 2018 ispor barcelona ispor europe 2018 ispor summit italy kings fund koonal koonal shah labour productivity latin america ldcs learning outcomes legal barriers legitimate legal bases life-cycle value long-term care lou garrison lung cancer mapping market access market competition markov matching mcda measurement for drugs medical research medicare medicine medicines mental health methodology mhra mlics modeling modern hta multi-indication drugs multi-indication pricing nancy devlin national health service net monetary benefit next generation sequencing nhs nice novel elements of value ohe oncology oncology medicines open source orphan drugs outcome-based payments outcomes outcomes-based contracting patient access schemes patient involvement patient reported outcomes patient-centred care patient-reported outcomes patients pay-for-performance payers payment mechanisms payors pbrsa personalized medicine pharm pharmaceutical pharmaceutical industry pharmaceutical innovation pharmaceutical r&d. pharmaceutical regulation pharmaceuticals pharmacoeconomics policy politics pprs preferences prescription drug presentation presentations price and reimbursement price discrimination prices pricing procurement professional training proms proms conference public public attitudes public preferences qaly qaly's qalys qualitative analysis quality quality of life r&d r&d incentives rare diseases rates of return real option value real world evidence real-world data real-world evidence regulators reimbursement research research and development resistance revenue rewards risk risperidone royal brompton screening second generation antipsychotics social surplus specialised care spillovers stated preference stated preferences static and dynamic efficiency stratified medicine supplementary patent certificates surplus sustainability sweden systematic review taiwan technology therapeutic added value third plenary session time trade off time trade-off transparency triangulating developers tto tto valuations of health states uae uhc uk universal health coverage unmet need uptake uptake curves us usa utilities vaccines valuation value value in health value of diagnostic information value of knowing value-based pricing value-based pricing and reimbursement vbp visual analogue scale washington dc weighted cea weighted qalys welfare states wellbeing world health organisation İçer …less